Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Transplantation

Free Subscription Articles published in J Hepatol Retrieve available abstracts of 141 articles: HTML format

Single Articles

June 2024
1. NORMAN JS, Mehta N
   Reply to: "Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score".
   J Hepatol. 2024;80:e273-e274.
   PubMed    
   
   
   May 2024
2. SPADA M, Angelico R, Trapani S, Masiero L, et al
   Reply to: "Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding".
   J Hepatol. 2024 May 15:S0168-8278(24)00346-5. doi: 10.1016/j.jhep.2024.
   PubMed    
   
   
   
3. GAMBELLA A, Salvi M, Molinari F
   Response to: Application of Digital Pathology in Liver Transplantation.
   J Hepatol. 2024 May 15:S0168-8278(24)00350-7. doi: 10.1016/j.jhep.2024.
   PubMed    
   
   
   
4. MULLER X, Rossignol G, Boulanger N, Mohkam K, et al
   In situ or ex situ split: Does it all come down to static cold storage?
   J Hepatol. 2024;80:e210-e211.
   PubMed    
   
   
   March 2024
5. LI Y, Yang F, Liu K
   Application of Digital Pathology in Liver Transplantation.
   J Hepatol. 2024 Mar 23:S0168-8278(24)00207-1. doi: 10.1016/j.jhep.2024.
   PubMed    
   
   
   
6. LAMARQUE C, Segaux L, Bachellier P, Buchard B, et al
   Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study.
   J Hepatol. 2024 Mar 21:S0168-8278(24)00202-2. doi: 10.1016/j.jhep.2024.
   PubMed     Abstract available
   
   
   
7. GAMBELLA A, Salvi M, Molinaro L, Patrono D, et al
   Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms.
   J Hepatol. 2024;80:495-504.
   PubMed     Abstract available
   
   
   February 2024
8. MARTIN-MATEOS R, Martinez-Arenas L, Carvalho-Gomes A, Aceituno L, et al
   Multidrug-resistant bacterial infections after liver transplantation: prevalence, impact, and risk factors.
   J Hepatol. 2024 Feb 28:S0168-8278(24)00128-4. doi: 10.1016/j.jhep.2024.
   PubMed     Abstract available
   
   
   
9. DE VILLE DE GOYET J
   Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: outframing and concluding: Comment on:Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period. Spada M,
   J Hepatol. 2024 Feb 12:S0168-8278(24)00126-0. doi: 10.1016/j.jhep.2024.
   PubMed    
   
   
   
10. SOIN A, Lesurtel M, Clavien PA
    To the editor: Reply to the letter by Liu et al. entitled "Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: A meta-analysis".
    J Hepatol. 2024 Feb 8:S0168-8278(24)00101-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    January 2024
11. LAUTERIO A, Cillo U, De Carlis R, Bernasconi D, et al
    Reply to: "Outcome of in-situ split liver transplantation in Italy over the last 25 years: an alternative analysis and personal view".
    J Hepatol. 2024 Jan 25:S0168-8278(24)00057-6. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    
12. TABRIZIAN P, Abdelrahim M, Schwartz M
    Immunotherapy and Transplantation for Hepatocellular Carcinoma.
    J Hepatol. 2024 Jan 20:S0168-8278(24)00053-9. doi: 10.1016/j.jhep.2024.
    PubMed    
    
    
    December 2023
13. NORMAN JS, Mehta N
    Reply to: Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Dec 26:S0168-8278(23)05371-0. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
14. SPADA M, Angelico R, Trapani S, Masiero L, et al
    Tailoring allocation policies and improving access to pediatric liver transplantation over a 16-year period.
    J Hepatol. 2023 Dec 18:S0168-8278(23)05308-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
15. SMEETS JJH, van Malenstein H, van der Merwe S, Nevens F, et al
    SARS-CoV-2 anti-spike IgG antibodies are present in all liver transplant recipients after fifth vaccine dose.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05362-X. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
16. PARENTE A, Jiao C, Eden J, Dutkowski P, et al
    machine perfusion, randomized controlled trials, liver transplantation, immune cellsPerfusate immune cell profiling during machine perfusion - A new tool to link risk and immune response after liver transplantation?
    J Hepatol. 2023 Dec 16:S0168-8278(23)05364-3. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
17. HAHN M, Herber A, Berg T, Seehofer D, et al
    Enhancing HCC Recurrence Prediction after Liver Transplantation: from DCP plus AFP-L3 model to GALAD Score.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05357-6. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
18. DE CARLIS R, Lauterio A, Bernasconi D, Taner B, et al
    Reply to: "Excellent long-term outcomes after sequential hypothermic and normothermic machine perfusion challenges the importance of functional donor warm ischemia time in DCD liver transplantation": Further comments on the changing role of donor warm
    J Hepatol. 2023;79:e245-e247.
    PubMed    
    
    
    November 2023
19. PARENTE A, Dondossola D, Dutkowski P, Schlegel A, et al
    Current evidence on the beneficial HOPE-effect based on systematic reviews and meta-analyses in liver transplantation.
    J Hepatol. 2023 Nov 10:S0168-8278(23)05233-9. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
20. LIU J, Qian J, Yang Z, Zhou L, et al
    Patients with Hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation:A meta-analysis.
    J Hepatol. 2023 Nov 6:S0168-8278(23)05231-5. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    October 2023
21. MURRAY SM, Pose E, Wittner M, Londono MC, et al
    Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and in liver transplant recipients.
    J Hepatol. 2023 Oct 18:S0168-8278(23)05174-7. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
22. DE VILLE DE GOYET J
    Outcome of in-situ split liver transplantation in Italy over the last 25 years : an alternative analysis and personal view.
    J Hepatol. 2023 Oct 12:S0168-8278(23)05151-6. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
23. SHA M, Cao J, Xia Q
    Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Oct 9:S0168-8278(23)05162-0. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    September 2023
24. ABERG F, Sallinen V, Tuominen S, Adam R, et al
    Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity-score matched intention-to-treat analysis.
    J Hepatol. 2023 Sep 16:S0168-8278(23)05100-0. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
25. CHOUDHARY NS, Dhampalwar S, Saraf N, Soin AS, et al
    Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
    J Hepatol. 2023 Sep 15:S0168-8278(23)05098-5. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
26. NORMAN JS, Li PJ, Kotwani P, Shui AM, et al
    AFP-L3 and DCP Strongly Predict Early Hepatocellular Carcinoma Recurrence After Liver Transplantation.
    J Hepatol. 2023 Sep 6:S0168-8278(23)05074-2. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
27. HERNAEZ R, Karvellas CJ, Liu Y, Sacleux SC, et al
    The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure.
    J Hepatol. 2023;79:717-727.
    PubMed     Abstract available
    
    
    
28. EDEN J, Dutkowski P, Schlegel A
    Reply to: "How many liver grafts could be recovered after implementation of donation after cardiac death in Germany?".
    J Hepatol. 2023;79:e120-e121.
    PubMed    
    
    
    
29. EDEN J, von Felten S, Dutkowski P, Schlegel A, et al
    Reply to: "A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation".
    J Hepatol. 2023;79:e116-e118.
    PubMed    
    
    
    
30. SHARMA N, Pandey S, Yadav M, Mathew B, et al
    Biomolecular map of albumin identifies signatures of severity and early mortality in acute liver failure.
    J Hepatol. 2023;79:677-691.
    PubMed     Abstract available
    
    
    
31. HAKEEM AR, Taylor R, Prasad R
    Comment on "Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicentre analysis of the US, the UK, and Canada".
    J Hepatol. 2023;79:e112-e114.
    PubMed    
    
    
    
32. CZIGANY Z, Michalski CW
    A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation.
    J Hepatol. 2023;79:e114-e116.
    PubMed    
    
    
    August 2023
33. TANG G, Zhang L, Zhou R
    Letter to the Editor: Machine perfusion techniques for liver transplantation - A meta-analysis of the first seven randomized controlled trials.
    J Hepatol. 2023 Aug 8:S0168-8278(23)05045-6. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
34. 
    EASL Clinical Practice Guidelines on acute-on-chronic liver failure.
    J Hepatol. 2023;79:461-491.
    PubMed     Abstract available
    
    
    
35. KARTOUN U
    Fairness metrics: Additional principles to consider for improving MELD.
    J Hepatol. 2023;79:e80-e81.
    PubMed    
    
    
    July 2023
36. VAN LEEUWEN OB, Bodewes SB, Porte RJ, de Meijer VE, et al
    Excellent long-term outcome after sequential hypothermic and normothermic machine perfusion challenges the importance of functional donor warm ischemia time in DCD liver transplantation.
    J Hepatol. 2023 Jul 27:S0168-8278(23)05004-3. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
37. LAUTERIO A, Cillo U, Spada M, Trapani S, et al
    Improving outcomes of in situ split liver transplantation in Italy over the last 25 years.
    J Hepatol. 2023 Jul 27:S0168-8278(23)04988-7. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    June 2023
38. BRAADLAND PR, Bergquist A, Kummen M, Bossen L, et al
    Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation.
    J Hepatol. 2023 Jun 14:S0168-8278(23)00415-4. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
39. LIM WH, Ng CH, Hao Tan DJ, Tseng M, et al
    Natural history of NASH cirrhosis in liver transplant waitlist registrants.
    J Hepatol. 2023 Jun 10:S0168-8278(23)00412-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
40. PARENTE A, Tirotta F, Pini A, Eden J, et al
    Machine perfusion techniques for liver transplantation - A meta-analysis of the first seven randomized controlled trials.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00399-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
41. KAPLAN A, Korenjak M, Brown RS Jr
    Post-liver transplantation patient experience.
    J Hepatol. 2023;78:1234-1244.
    PubMed     Abstract available
    
    
    
42. BHAT M, Rabindranath M, Chara BS, Simonetto DA, et al
    Artificial intelligence, machine learning, and deep learning in liver transplantation.
    J Hepatol. 2023;78:1216-1233.
    PubMed     Abstract available
    
    
    
43. MONTANO-LOZA AJ, Rodriguez-Peralvarez ML, Pageaux GP, Sanchez-Fueyo A, et al
    Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation.
    J Hepatol. 2023;78:1199-1215.
    PubMed     Abstract available
    
    
    
44. DE CARLIS R, Paolo Muiesan, Taner B
    Donation after circulatory death: Novel strategies to improve the liver transplant outcome.
    J Hepatol. 2023;78:1169-1180.
    PubMed     Abstract available
    
    
    
45. GERMANI G, Mathurin P, Lucey MR, Trotter J, et al
    Early liver transplantation for severe acute alcohol-related hepatitis after more than a decade of experience.
    J Hepatol. 2023;78:1130-1136.
    PubMed     Abstract available
    
    
    
46. SOIN A, Lesurtel M, Bhangui P, Cocchi L, et al
    Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?
    J Hepatol. 2023;78:1124-1129.
    PubMed     Abstract available
    
    
    
47. ARTRU F, Goldberg D, Kamath PS
    Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation?
    J Hepatol. 2023;78:1118-1123.
    PubMed     Abstract available
    
    
    
48. TANDON P, Zanetto A, Piano S, Heimbach JK, et al
    Liver transplantation in the patient with physical frailty.
    J Hepatol. 2023;78:1105-1117.
    PubMed     Abstract available
    
    
    
49. BURRA P
    The changing world of liver transplantation.
    J Hepatol. 2023;78:1087-1088.
    PubMed    
    
    
    
50. SCHLEGEL A, Mergental H, Fondevila C, Porte RJ, et al
    Machine perfusion of the liver and bioengineering.
    J Hepatol. 2023;78:1181-1198.
    PubMed     Abstract available
    
    
    
51. TANER T, Hilscher MB, Broda CR, Drenth JPH, et al
    Issues in multi-organ transplantation of the liver with kidney or heart in polycystic liver-kidney disease or congenital heart disease: Current practices and immunological aspects.
    J Hepatol. 2023;78:1157-1168.
    PubMed     Abstract available
    
    
    
52. KASAHARA M, Hong JC, Dhawan A
    Evaluation of living donors for hereditary liver disease (siblings, heterozygotes).
    J Hepatol. 2023;78:1147-1156.
    PubMed     Abstract available
    
    
    May 2023
53. EDEN J, Sousa Da Silva R, Cortes-Cerisuelo M, Croome K, et al
    Utilization of livers donated after circulatory death for transplantation - An international comparison.
    J Hepatol. 2023;78:1007-1016.
    PubMed     Abstract available
    
    
    April 2023
54. GUO Z, Zhao Q, Jia Z, Huang C, et al
    A randomized-controlled trial of ischemia-free liver transplantation for end-stage liver disease.
    J Hepatol. 2023 Apr 20:S0168-8278(23)00233-7. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
55. SCHLEGEL A, Mueller M, Muller X, Eden J, et al
    A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation.
    J Hepatol. 2023;78:783-793.
    PubMed     Abstract available
    
    
    March 2023
56. MOOSBURNER S, Sauer IM, Weiss B, Pratschke J, et al
    How many liver transplantations could be recovered after implementation of donation after cardiac death in Germany?
    J Hepatol. 2023 Mar 11:S0168-8278(23)00176-9. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
57. GE J, Kim WR, Lai JC, Kwong AJ, et al
    Response to: "Towards optimally replacing the current version of MELD".
    J Hepatol. 2023;78:e100-e101.
    PubMed    
    
    
    
58. KARTOUN U
    Towards optimally replacing the current version of MELD.
    J Hepatol. 2023;78:e98-e99.
    PubMed    
    
    
    February 2023
59. LUXENBURGER H, Reeg DB, Lang-Meli J, Reinscheid M, et al
    Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients.
    J Hepatol. 2023 Feb 17:S0168-8278(23)00095-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    January 2023
60. FUNDORA Y, Hessheimer AJ, Del Prete L, Maroni L, et al
    Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis.
    J Hepatol. 2023 Jan 20:S0168-8278(23)00018-1. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    December 2022
61. LEE BP, Dodge JL, Terrault NA
    Liver Transplant for Alcohol-Associated Liver Disease Continues to Rise 2-Years into the COVID-19 Pandemic Especially Among Young Adults.
    J Hepatol. 2022 Dec 22:S0168-8278(22)03460-2. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
62. IVANICS T, Wallace D, Claasen MPAW, Patel MS, et al
    Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicenter analysis of the US, the UK, and Canada.
    J Hepatol. 2022;77:1607-1618.
    PubMed     Abstract available
    
    
    November 2022
63. ARTZNER T, Belli LS, Faitot F, Jalan R, et al
    Attitudes toward liver transplantation for ACLF-3 patients determine equity of access.
    J Hepatol. 2022 Nov 5. pii: S0168-8278(22)03286.
    PubMed    
    
    
    September 2022
64. LASCARIS B, de Meijer VE, Porte RJ
    Normothermic liver machine perfusion as a dynamic platform for regenerative purposes: What does the future have in store for us?
    J Hepatol. 2022;77:825-836.
    PubMed     Abstract available
    
    
    
65. CHEN ZX, Liu SY, Tong XM
    Preoperative prediction of microvascular invasion: Is invasive biopsy of HCC necessary?
    J Hepatol. 2022;77:892-893.
    PubMed    
    
    
    July 2022
66. MARJOT T, Eberhardt CS, Boettler T, Belli LS, et al
    Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper.
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02942.
    PubMed    
    
    
    June 2022
67. GE J, Kim WR, Lai JC, Kwong AJ, et al
    "Beyond MELD" - Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation.
    J Hepatol. 2022;76:1318-1329.
    PubMed     Abstract available
    
    
    May 2022
68. SESSA M, Lai Q, Germinario G, Ravaioli M, et al
    Authors reply to the Letter to the Editor "Impact of MELD 30-allocation policy on liver transplant outcomes in Italy: Considerations".
    J Hepatol. 2022 May 7. pii: S0168-8278(22)00270.
    PubMed    
    
    
    
69. MUCKE MM, Zeuzem S
    The recent outbreak of acute severe hepatitis in children of unknown origin - what is known so far.
    J Hepatol. 2022 May 6. pii: S0168-8278(22)00271.
    PubMed     Abstract available
    
    
    
70. WANG KC, Sun LY, Wang MD
    Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00263.
    PubMed    
    
    
    
71. LEE BP, Cullaro G, Vosooghi A, Yao F, et al
    Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database.
    J Hepatol. 2022;76:1122-1126.
    PubMed     Abstract available
    
    
    April 2022
72. DAVIDOV Y, Indenbaum V, Tsaraf K, Cohen-Ezra O, et al
    A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.
    J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00237.
    PubMed     Abstract available
    
    
    March 2022
73. MAGYAR CTJ, Beldi G, Banz V
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy: Considerations.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00186.
    PubMed    
    
    
    
74. CHOI JY, Kim JH, Kim JM, Kim HJ, et al
    Outcomes of living liver donors are worse than those of matched healthy controls.
    J Hepatol. 2022;76:628-638.
    PubMed     Abstract available
    
    
    February 2022
75. TONIUTTO P, Falleti E, Cmet S, Cussigh A, et al
    Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    J Hepatol. 2022 Feb 23. pii: S0168-8278(22)00122.
    PubMed     Abstract available
    
    
    
76. MONTANO-LOZA AJ, Ronca V, Ebadi M, Hansen BE, et al
    Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.
    J Hepatol. 2022 Feb 7. pii: S0168-8278(22)00067.
    PubMed     Abstract available
    
    
    
77. FOERSTER F, Gairing SJ, Muller L, Galle PR, et al
    NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
    J Hepatol. 2022;76:446-457.
    PubMed     Abstract available
    
    
    January 2022
78. THULUVATH PJ, Li F
    Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!"
    J Hepatol. 2022;76:242-243.
    PubMed    
    
    
    
79. VERMA N, Mehtani R, Duseja A
    Universal definition and prognostication in acute-on-chronic liver failure - an unmet need!
    J Hepatol. 2022;76:241-242.
    PubMed    
    
    
    December 2021
80. BELLI LS, Perricone G, Jalan R
    Reply to: Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation. Reply letter.
    J Hepatol. 2021 Dec 28. pii: S0168-8278(21)02293.
    PubMed    
    
    
    November 2021
81. RAVAIOLI M, Lai Q, Sessa M, Ghinolfi D, et al
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
    J Hepatol. 2021 Nov 10. pii: S0168-8278(21)02166.
    PubMed     Abstract available
    
    
    
82. LEE BT, Fiel MI, Schiano TD
    Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective.
    J Hepatol. 2021;75:1203-1216.
    PubMed     Abstract available
    
    
    
83. FERRER-FABREGA J, Sampson-Davila J, Forner A, Sapena V, et al
    Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.
    J Hepatol. 2021;75:1154-1163.
    PubMed     Abstract available
    
    
    October 2021
84. SCHLEGEL A, van Reeven M, Croome K, Parente A, et al
    A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation.
    J Hepatol. 2021 Oct 13. pii: S0168-8278(21)02110.
    PubMed     Abstract available
    
    
    
85. RUSSO FP, Izzy M, Rammohan A, Kirchner VA, et al
    Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS).
    J Hepatol. 2021 Oct 12. pii: S0168-8278(21)02107.
    PubMed     Abstract available
    
    
    
86. RABINOWICH L, Shibolet O, Katchman H
    Effectiveness of SARS-Cov-2 vaccination in liver transplanted patients: time for comprehensive data analysis.
    J Hepatol. 2021 Oct 8. pii: S0168-8278(21)02102.
    PubMed    
    
    
    
87. MALLET V, Beeker N, Bouam S, Sogni P, et al
    Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.
    J Hepatol. 2021;75:848-855.
    PubMed     Abstract available
    
    
    September 2021
88. ARTRU F, le Goffic C, Pageaux GP, Saliba F, et al
    Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation.
    J Hepatol. 2021 Sep 15. pii: S0168-8278(21)02034.
    PubMed    
    
    
    
89. AGOPIAN VG, Markovic D
    Reply to: correspondence regarding "Multicenter validation of the liver graft assessment following transplantation (L-GrAFT) score for assessment of early allograft dysfunction".
    J Hepatol. 2021;75:732-735.
    PubMed    
    
    
    
90. EEROLA V, Aberg F, Sallinen V
    An unequivocal formula to calculate L-GrAFT score is needed.
    J Hepatol. 2021;75:731-732.
    PubMed    
    
    
    August 2021
91. THULUVATH PJ, Robarts P, Chauhan M
    Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02002.
    PubMed     Abstract available
    
    
    
92. VIONNET J, Miquel R, Abraldes JG, Wall J, et al
    Non-invasive alloimmune risk stratification of long-term liver transplant recipients.
    J Hepatol. 2021 Aug 23. pii: S0168-8278(21)02001.
    PubMed     Abstract available
    
    
    
93. GUARINO M, Cossiga V, Esposito I, Alessandro F, et al
    Effectiveness of SARS-Cov-2 vaccination in liver transplanted patients: the debate is open!
    J Hepatol. 2021 Aug 3. pii: S0168-8278(21)01961.
    PubMed    
    
    
    July 2021
94. PENRICE DD, Havlichek D 3rd, Kamath PS, Simonetto DA, et al
    Outcomes Following Liver Transplant in Adults with Telomere Biology Disorders.
    J Hepatol. 2021 Jul 28. pii: S0168-8278(21)01951.
    PubMed    
    
    
    
95. BETTINGER D, Thimme R, Schultheiss M
    Reply: TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01891.
    PubMed    
    
    
    
96. BURRA P, Samuel D, Sundaram V, Duvoux C, et al
    Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.
    J Hepatol. 2021;75 Suppl 1:S178-S190.
    PubMed     Abstract available
    
    
    
97. ADAMS DH
    EASL recognition award recipient 2021: Prof. Patrizia Burra.
    J Hepatol. 2021;75:5-6.
    PubMed    
    
    
    
98. STEPHENS C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, et al
    Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
    J Hepatol. 2021;75:86-97.
    PubMed     Abstract available
    
    
    June 2021
99. RELA M, Rammohan A
    Why Are There So Many Liver Transplants from Living Donors In Asia And So Few In Europe And The US?
    J Hepatol. 2021 Jun 7. pii: S0168-8278(21)00408.
    PubMed     Abstract available
    
    
    
100. BERNAL W, McPhail MJ
     Acute liver failure.
     J Hepatol. 2021;74:1489-1490.
     PubMed    
     
     
     
101. ABDALLAH MA, Kuo YF, Asrani S, Wong RJ, et al
     Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
     J Hepatol. 2021;74:1355-1361.
     PubMed     Abstract available
     
     
     May 2021
102. MATHURIN P
     Early liver transplantation for acute alcoholic hepatitis: we can't say no.
     J Hepatol. 2021 May 28. pii: S0168-8278(21)00354.
     PubMed     Abstract available
     
     
     
103. GIANNINI EG, Marenco S
     High acceptance rate of COVID-19 vaccination in liver transplant recipients.
     J Hepatol. 2021 May 27. pii: S0168-8278(21)00344.
     PubMed    
     
     
     
104. RUDLER M, Savier E, Alioua I, Sultanik P, et al
     TIPS and liver transplantation should always be discussed together.
     J Hepatol. 2021 May 26. pii: S0168-8278(21)00347.
     PubMed    
     
     
     
105. CORNBERG M, Eberhardt CS
     Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.
     J Hepatol. 2021 May 25. pii: S0168-8278(21)00342.
     PubMed    
     
     
     
106. DE GASPERI A, Zorzi A
     Cardiac evaluation before liver transplantation: a step forward?
     J Hepatol. 2021 May 10. pii: S0168-8278(21)00299.
     PubMed    
     
     
     
107. MEDERACKE YS, Nienen M, Jarek M, Geffers R, et al
     T cell receptor repertoires within liver allografts are different to those in the peripheral blood.
     J Hepatol. 2021;74:1167-1175.
     PubMed     Abstract available
     
     
     April 2021
108. BELLI LS, Duvoux C, Artzner T, Bernal W, et al
     Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS).
     J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00261.
     PubMed     Abstract available
     
     
     
109. RABINOWICH L, Grupper A, Baruch R, Ben-Yehoyada M, et al
     Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
     J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00255.
     PubMed     Abstract available
     
     
     
110. RODRIGUEZ-PERALVAREZ M, Colmenero J, Salcedo M
     Reply to: Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients.
     J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00239.
     PubMed    
     
     
     
111. AGOPIAN VG, Markovic D, Klintmalm GB, Saracino G, et al
     Multicenter validation of the liver graft assessment following transplantation (L-GrAFT) score for assessment of early allograft dysfunction.
     J Hepatol. 2021;74:881-892.
     PubMed     Abstract available
     
     
     March 2021
112. POSE E, Torrents A, Reverter E, Perez-Campuzano V, et al
     A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.
     J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00175.
     PubMed     Abstract available
     
     
     
113. JOYE R, Lador F, Aggoun Y, Farhat N, et al
     Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.
     J Hepatol. 2021;74:742-747.
     PubMed     Abstract available
     
     
     February 2021
114. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
     EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
     J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
     PubMed     Abstract available
     
     
     
115. WEBB GJ, Moon AM, Barnes E, Barritt AS 4th, et al
     Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients.
     J Hepatol. 2021 Feb 5. pii: S0168-8278(21)00085.
     PubMed    
     
     
     January 2021
116. DE MARTIN E, Coilly A, Chazouilleres O, Roux O, et al
     Early liver transplantation for corticosteroid non-responders in acute severe autoimmune hepatitis: the SURFASA score.
     J Hepatol. 2021 Jan 24. pii: S0168-8278(21)00041.
     PubMed     Abstract available
     
     
     
117. RACHWAN RJ, Kutkut I, Timsina LR, Bou Chaaya RG, et al
     CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates.
     J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00016.
     PubMed     Abstract available
     
     
     
118. RAHIM MN, Theocharidou E, Yen Lau KG, Ahmed R, et al
     Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
     J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00005.
     PubMed     Abstract available
     
     
     
119. GOLDBERG D, Mantero A, Newcomb C, Delgado C, et al
     Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score.
     J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00004.
     PubMed     Abstract available
     
     
     December 2020
120. AVOLIO AW, Lai Q, Cillo U, Romagnoli R, et al
     L-GrAFT and EASE scores in liver transplantation. Need for a reciprocal external validation and comparison with other scores.
     J Hepatol. 2020 Dec 16. pii: S0168-8278(20)33848.
     PubMed    
     
     
     
121. MANKA P, Canbay A, Bechmann LP
     Model for end-stage liver disease-sodium in acute-on-chronic liver failure.
     J Hepatol. 2020;73:1578-1579.
     PubMed    
     
     
     November 2020
122. KRASSENBURG LAP, Maan R, Ramji A, Manns MP, et al
     Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
     J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33805.
     PubMed     Abstract available
     
     
     
123. MEHTA N, Dodge JL, Roberts JP, Yao FY, et al
     A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
     J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33750.
     PubMed     Abstract available
     
     
     
124. AQEL B, Wijarnpreecha K, Pungpapong S, Taner CB, et al
     Outcomes following transplantation of HCV-seropositive livers to HCV-seronegative recipients.
     J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33754.
     PubMed     Abstract available
     
     
     August 2020
125. 
     EASL recommendations on treatment of hepatitis C - Final update of the series.
     J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30548.
     PubMed     Abstract available
     
     
     June 2020
126. PAPATHEODORIDIS GV, Dalekos GN, Idilman R, Sypsa V, et al
     Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
     J Hepatol. 2020 Jun 15. pii: S0168-8278(20)30382.
     PubMed     Abstract available
     
     
     May 2020
127. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
     Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
     J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
     PubMed     Abstract available
     
     
     April 2020
128. MAZUMDER NR, Celaj S, Atiemo K, Daud A, et al
     Liver-related mortality is similar among men and women with cirrhosis.
     J Hepatol. 2020 Apr 25. pii: S0168-8278(20)30235.
     PubMed     Abstract available
     
     
     
129. CORPECHOT C, Chazouilleres O, Belnou P, Montano-Loza AJ, et al
     Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
     J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30205.
     PubMed     Abstract available
     
     
     March 2020
130. VERNA EC, Morelli G, Terrault NA, Lok AS, et al
     DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
     J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30193.
     PubMed     Abstract available
     
     
     
131. LAI JC, Dodge JL, Kappus MR, Dunn MA, et al
     Changes in frailty are associated with waitlist mortality in patients with cirrhosis.
     J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30191.
     PubMed     Abstract available
     
     
     
132. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
     Portopulmonary hypertension in the current era of pulmonary hypertension management.
     J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119.
     PubMed     Abstract available
     
     
     February 2020
133. MAZZAFERRO V, Gorgen A, Roayaie S, Droz Dit Busset M, et al
     Liver resection and transplantation for intrahepatic cholangiocarcinoma.
     J Hepatol. 2020;72:364-377.
     PubMed     Abstract available
     
     
     
134. VIBERT E, Schwartz M, Olthoff KM
     Advances in resection and transplantation for hepatocellular carcinoma.
     J Hepatol. 2020;72:262-276.
     PubMed     Abstract available
     
     
     July 2019
135. GOET JC, Floreani A, Verhelst X, Cazzagon N, et al
     Validation, Clinical Utility and Limitations of the Amsterdam-Oxford Model for Primary Sclerosing Cholangitis.
     J Hepatol. 2019 Jul 3. pii: S0168-8278(19)30384.
     PubMed     Abstract available
     
     
     June 2019
136. LIU Y, Lu T, Zhang C, Xu J, et al
     Activation of YAP Attenuates Hepatic Damage and Fibrosis in Liver Ischemia-Reperfusion Injury.
     J Hepatol. 2019 Jun 12. pii: S0168-8278(19)30344.
     PubMed     Abstract available
     
     
     May 2019
137. FONTANELLAS A, Avila MA, Anderson KE, Deybach JC, et al
     Current and innovative emerging therapies for porphyrias with hepatic involvement.
     J Hepatol. 2019 May 15. pii: S0168-8278(19)30282.
     PubMed     Abstract available
     
     
     
138. JI F, Yeo YH, Wei MT, Ogawa E, et al
     Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
     J Hepatol. 2019 May 13. pii: S0168-8278(19)30279.
     PubMed     Abstract available
     
     
     April 2019
139. MOUNA L, Rossignol E, Tateo M, Coilly A, et al
     Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.
     J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30136.
     PubMed    
     
     
     
140. KIM SU, Seo YS, Lee HA, Kim MN, et al
     A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea.
     J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30222.
     PubMed     Abstract available
     
     
     January 2019
141. DOYLE A, Gorgen A, Muaddi H, Aravinthan AD, et al
     Outcomes of Radiofrequency Ablation as First-Line Therapy for Hepatocellular Carcinoma less than 3 cm in Potentially Transplantable Patients.
     J Hepatol. 2019 Jan 4. pii: S0168-8278(19)30001.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Transplantation is free of charge.